NIKKEI 225
38,598.12 -105.39 (-0.27%) HANG SENG
18,425.67 -51.13 (-0.28%) CRUDE OIL
75.54 -0.01 (-0.01%) GOLD FUTURES
2,390.90 0.00 (0.00%) DOW
38,886.17 +78.84 (+0.20%) Bitcoin GBP
55,331.29 -353.25 (-0.63%)
BEAM Jun 2024 24.000 call
| Previous close | 2.0000 |
| Open | 1.2700 |
| Bid | 0.0000 |
| Ask | 1.8500 |
| Strike | 24.00 |
| Expiry date | 2024-06-21 |
| Day's range | 1.2700 - 1.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 69 |
ZacksWhy Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GlobeNewswireBeam Therapeutics to Participate in Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, president of Beam, plans to participate in a fireside chat during the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1:30 p.m. ET in New York City. A live webcast will be available in the investor section of the company's website at www.beamtx.com, and will be
- GlobeNewswire
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will report data highlighting the robust, closed and automated manufacturing process for BEAM-101, as deployed in the BEACON Phase 1/2 clinical trial, in a poster presentation at the European Hematology Association (EHA) Hybrid Congress, hosted virtually and in person in Madrid, Spain on Jun
